[{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"ALK \/ Otonomy","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Otonomy"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"KALEO INC","sponsor":"Optinose","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"KALEO INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"KALEO INC \/ Optinose","highestDevelopmentStatusID":"12","companyTruncated":"KALEO INC \/ Optinose"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genentech"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Glenmark Pharmaceuticals \/ Dr Reddy\u2019s Lab","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Dr Reddy\u2019s Lab"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Vivimed Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Vivimed Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivimed Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vivimed Labs \/ Not Applicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"ALK","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Otic Suspension","sponsorNew":"Otonomy \/ ALK","highestDevelopmentStatusID":"12","companyTruncated":"Otonomy \/ ALK"},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Intranasal","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/ Piper Sandler"},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/ Not Applicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Perrigo Company plc \/ Organon LLC","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Organon LLC"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"NF-?B","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Intersect ENT","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"Implant","sponsorNew":"Intersect ENT \/ Medtronic","highestDevelopmentStatusID":"12","companyTruncated":"Intersect ENT \/ Medtronic"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Corticosteroid","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Intersect ENT","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"","sponsorNew":"Intersect ENT \/ Medtronic","highestDevelopmentStatusID":"12","companyTruncated":"Intersect ENT \/ Medtronic"},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/ Not Applicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/ Not Applicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/ Not Applicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Spray","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/ Piper Sandler"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fennec Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fennec Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/ Not Applicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fennec Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Actor Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Glycine","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Actor Pharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Gel","sponsorNew":"Actor Pharma \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Actor Pharma \/ Cipla"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Film, Dispersible","sponsorNew":"Shilpa Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shilpa Medicare \/ Not Applicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Fennec Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor","highestDevelopmentStatusID":"12","companyTruncated":"Fennec Pharmaceuticals \/ Petrichor"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Thiosulfate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Fennec Pharmaceuticals","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.27000000000000002,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Norgine","highestDevelopmentStatusID":"12","companyTruncated":"Fennec Pharmaceuticals \/ Norgine"},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2024","type":"Divestment","leadProduct":"Betahistine Dimesilate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Eisai","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/ Not Applicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Eisai divested its rights for Merislon (betahistine mesilate), used to treat Meniere's syndrome, and muscle relaxant Myonal (eperisone hydrochloride) in Japan to Kaken.

                          Brand Name : Merislon

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 29, 2024

                          Lead Product(s) : Betahistine Dimesilate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Sponsor : Kaken Pharmaceuticals

                          Deal Size : $25.0 million

                          Deal Type : Divestment

                          blank

                          02

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Ciprofloxacin and dexamethasone otic suspension is indicated for treating acute otitis externa in pediatric, adult, and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa.

                          Brand Name : Ciprodex-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 25, 2024

                          Lead Product(s) : Ciprofloxacin,Dexamethasone

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Norgine will commercialize Pedmarqsi (sodium thiosulfate) in Europe, Australia, and New Zealand, the first approved therapy in the EU and UK to prevent cisplatin-induced ototoxicity.

                          Brand Name : Pedmarqsi

                          Molecule Type : Small molecule

                          Upfront Cash : $43.4 million

                          March 18, 2024

                          Lead Product(s) : Sodium Thiosulfate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Sponsor : Norgine

                          Deal Size : $271.6 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : The net proceeds will be used by the company for the commercialization of Pedmark (sodium thiosulfate), the only approved therapy for reducing the risk of hearing loss in pediatric cancer patients who receive treatment with platinum-based chemotherapy.

                          Brand Name : Pedmark

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 05, 2023

                          Lead Product(s) : Sodium Thiosulfate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Sponsor : Petrichor

                          Deal Size : $20.0 million

                          Deal Type : Financing

                          blank

                          05

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.

                          Brand Name : Nozohaem

                          Molecule Type : Small molecule

                          Upfront Cash : $48.6 million

                          September 05, 2023

                          Lead Product(s) : Glycine,Calcium

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Sponsor : Cipla

                          Deal Size : $48.6 million

                          Deal Type : Acquisition

                          blank

                          06

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Betahistine dihydrochloride is an antivertigo agent, which is act as the histamine receptor inhibitor, which is indicated for the reduction of recurrent vertigo episodes associated with Meniere's disease in patients 18 years old and above.

                          Brand Name : Betahistine Dihydrochloride-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 03, 2023

                          Lead Product(s) : Betahistine Dihydrochloride

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank